FCCC LOGO Faculty Publications
Wei W , Lin Y , Song Z , Xiao W , Chen L , Yin J , Zhou Y , Barta SK , Petrus M , Waldmann TA , Yang Y
A20 and RBX1 regulate brentuximab vedotin sensitivity in Hodgkin Lymphoma models
Clin Cancer Res. 2020 Aug 1;26(15) :4093-4106
PMID: 32299816    PMCID: PMC7549381    URL: https://www.ncbi.nlm.nih.gov/pubmed/32299816
Back to previous list
Abstract
PURPOSE: For refractory/relapsed Hodgkin lymphoma (HL) patients (roughly 20% of total cases), few effective therapeutic options exist. Currently, Brentuximab Vedotin (BV), a drug-conjugated anti-CD30 antibody, is one of the most effective approved therapy agents for these patients. However, many patients do not achieve complete remission and ultimately develop BV-resistant disease, -necessitating a more detailed understanding of the molecular circuitry that drives BV sensitivity and the mechanism of BV resistance. EXPERIMENTAL DESIGN: Here, we established a ubiquitin regulator-focused CRISPR library screening platform in HL and carried out a drug sensitization screen against BV to identify genes regulating BV treatment sensitivity. RESULTS: Our CRISPR library screens revealed the ubiquitin-editing enzymes A20 and RBX1 as key molecule effectors that regulate BV sensitivity in HL line L428. A20 negatively regulates NF-kappaB activity which is required to prevent BV cytotoxicity. In line with these results, the RNA-seq analysis of the BV-resistant single cell clones demonstrated a consistent upregulation of NF-kappaB signature genes, as well as the ABC transporter gene ABCB1. Mechanically, NF-kappaB regulates BV treatment sensitivity through mediating ABCB1 expression. Targeting NF-kappaB activity synergized well with BV in killing HL cell lines, augmented BV sensitivity and overcame BV resistance in vitro and in HL xenograft mouse models. CONCLUSIONS: Thus, our identification of this previously unrecognized mechanism provides novel knowledge of possible BV responsiveness and resistance mechanism in HL, as well as leads to promising hypothesis for the development of therapeutic strategies to overcome BV resistance in this disease.
Notes
Wei, Wei ORCID: https://orcid.org/0000-0002-6478-5973 Lin, Yuquan Song, Zhihui Xiao, Wenming Chen, Liqi Yin, Jiejing Zhou, Yan Barta, Stefan K Petrus, Michael Waldmann, Thomas A Yang, Yibin Journal Article United States Clin Cancer Res. 2020 Apr 16. pii: 1078-0432.CCR-19-4137. doi: 10.1158/1078-0432.CCR-19-4137.